🔴 Inovio Pharmaceuticals is trading 5.7% down; no verified cause identified

Inovio Pharmaceuticals is trading at $1.56, down 5.72%, with no verified Inovio-specific announcement explaining the November 4 decline.

• The FDA approval of VOCERYQ preceded a sharp rally, but available reporting does not establish it as the cause of this pullback.
• Biotech and broad-market indices are higher in the supplied context, so they do not explain the decline.
• No trading-volume information was provided.